158 results about "Cancer targeting" patented technology

Described herein are therapeutic targets expressed in cancer stem cells and methods for treating and diagnosing cancer by targeting such cells with antibodies, compounds, nucleic acid, or other therapeutic agent. In one embodiment described herein, therapeutic agents for the treatment of cancer are provided based on the identification of cancer stem cell targets. The present invention also includes therapeutic targets for cancer therapy and cancer stem cell-targeted therapy. The invention includes the treatment of cancer by the administration of compounds or agents that target cancer stem cells.

The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.

The invention discloses a plant anti-cancer targeting nano-preparation, and a preparation method of the nano-preparation. The nano-preparation comprises (by weight) 43-60% of human blood albumin, 1.5-7.5% of plant anti-cancer drug, 24-40% of hyaluronic acid with molecular weight of 3,000-1,800,000 Da, 3.5-15 % of nanoparticle stabilizer, and the balance of water. The preparation method includes preparation of hyaluronic acid-albumin conjugate; preparation of plant anti-cancer drug solution; and preparation of the targeting nano-preparation. The plant anti-cancer targeting nano-preparation has good stability and bio-targeting function.

Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.

The present invention describes small molecule ligand-drug conjugates and methods of using the small molecule ligand-drug conjugates for targeted treatment of cancer in a patient in need thereof. Further described are methods of sterilizing circulating tumor cells and determining drug concentration in cancer tissue.

The present invention is intended to provide a pharmaceutical for tumor treatment that stays specifically in interstitium for a long time and exhibits an effect, and provides a complex consisting of a substance having specific binding affinity for stroma and an antitumor compound bound to the substance via a linker.

Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.

The present invention relates to a methylene blue nanoparticle for bioimaging and photodynamic therapy, and a use thereof as a cancer therapeutic agent and a contrast agent. The methylene blue nanoparticle of the present invention for use as a topical cancer targeting photo therapeutic agent is composed of only a material of which the composition is clinically used or derived from human bodies, and thus a nanopreparation in which a barrier to clinical entry is low and the possibility of commercialization is very high, exhibits near-infrared fluorescence along with cancer targeting property, capacity of generating singlet oxygen and the like, and thus may be used for both bioimaging diagnosis such as optical imaging, and cancer targeting photodynamic therapy.

The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.

The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.

The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis.

The invention relates to development of novel application of existing magnetic Prussian blue nanoparticles to magnetic resonance imaging and targeting photothermal therapy for cancer. Magnetic Prussian blue is a traditional nano material and mainly comprises ferroferric oxide nano cores and Prussian blue nano shells. Prussian blue is an efficient near infrared light heat agent, and a clinical medicine with high biological safety in vivo. Ferroferric oxide has good magnetic resonance imaging and magnetic targeting effects, and has also been applied to the clinic. The existing preparation method of magnetic Prussian blue nanoparticles is mature, simple, green and low in cost. The invention develops novel application of magnetic Prussian blue nanoparticles to magnetic resonance imaging and targeting photothermal therapy for cancer, achieves the integration of utilization of the magnetic Prussian blue nanoparticles to targeting diagnosis and treatment for cancer, and has extremely broad application prospect in diagnosis and treatment of cancer.

The invention discloses a beta-carboline-cycloenone derivative with a structure as shown in a general formula which is described in the specification. According to the invention, an electron-donatinggroup is introduced into a proper part of beta-carboline, and the 3-site amino group of beta-carboline is connected with cycloenone having anti-tumor activity by utilizing a carbamate bond, so the novel beta-carboline-cycloenone derivative is designed and synthesized. The derivative realizes pH and GSH dual-response fluorescence imaging and diagnosis in a tumor microenvironment, and can selectively target to GSTpi highly-expressed in tumor tissue, so tumor cell proliferation can be significantly inhibited. Such a pH/GSH dual-response fluorescence and cancer-targeting treatment diagnosis and treatment drug provides a new choice for accurate diagnosis and targeting treatment of tumors, and broadens the application of multifunctional molecules in accurate medical treatment.

The present invention relates to an ultrasound contrast agent with drug-encapsulating nanoparticles and a method for preparing the same that increase drug delivery capabilities and drug penetration effects. According to the present invention, exposure to the focussed ultrasound triggers the cavitation of an ultrasound contrast agent, resulting in the local release of drug-encapsulating nanoparticles, which are conjugated onto the surface of the ultrasound contrast agent, and enhanced penetration of nanoparticles and drug delivery capabilities. Moreover, the present invention simultaneously and selectively diagnoses and treats cancers by conjugation cancer-targeting ligands on the surface of nanoparticles.

[Problem] To provide a novel and effective method for treating cancer, method for preventing cancer, and method for suppressing metastasis by targeting cancer stem cells, the methods being capable of labeling and damaging cancer stem cells; and to provide a method for damaging and a method for identifying cancer stem cells. [Solution] The present invention provides a viral vector having a promoter that is specifically expressed in cancer stem cells and that can be used for treatment and diagnosis. Furthermore, the present invention provides a method for treating cancer, a method for preventing cancer, and a method for suppressing metastasis using this viral vector, and further provides a method for damaging and a method for identifying cancer stem cells. Furthermore, the present invention provides a labeling agent and a toxic agent for cancer stem cells containing the vector as the active ingredient, and further provides a diagnostic drug, a therapeutic drug, and a metastasis suppressant for cancer.

The present invention relates to a method of delivering an agent to a cancer cell, comprising: (a) obtaining a peptide that selectively binds to a cancer cell, wherein the peptide comprises a cancer targeting motif having the amino acid sequence of SEQ ID NO: 1, wherein the peptide is attached or fused to an agent that one desires to target to a cancer cell; and (b) exposing the peptide to a population of cells suspected of containing cancer cells. The present invention also relates to a kit for applying the above method, comprising a peptide that binds to a cancer cell, wherein the peptide comprises a cancer targeting motif having the amino acid sequence of SEQ ID NO: 1.